Jean-François Chateil

Jean-François Chateil

Auto-generated profile, based on publicly available information

Jean-François Chateil

University of Bordeaux, CNRS, CRMSB, UMR 5536, F-33000 Bordeaux, France

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2014 in British Journal of Cancer
Verified
Journal Article
Open access
NJN Journy
N Journy
JRJ-L Rehel
J-L Rehel
HPH Ducou Le Pointe
H Ducou Le Pointe
CLC Lee
C Lee
HBH Brisse
H Brisse
MBM-O Bernier
M-O Bernier
Recent epidemiological results suggested an increase of cancer risk after receiving computed tomography (CT) scans in childhood or adolescence. Their interpretation is questioned due to the lack of information about the reasons for examination. Our objective was to estimate the cancer risk related to childhood CT scans, and examine how cancer-predisposing factors (PFs) affect assessment of the radiation-related risk. The cohort included 67,274 children who had a first scan before the age of 10 years from 2000 to 2010 in 23 French departments. Cumulative X-rays doses were estimated from radiology protocols. Cancer incidence was retrieved through the national registry of childhood cancers; PF from discharge diagnoses. During a mean follow-up of 4 years, 27 cases of tumours of the central nervous system, 25 of leukaemia and 21 of lymphoma were diagnosed; 32% of them among children with PF. Specific patterns of CT exposures were observed according to PFs. Adjustment for PF reduced the excess risk estimates related to cumulative doses from CT scans. No significant excess risk was observed in relation to CT exposures. This study suggests that the indication for examinations, whether suspected cancer or PF management, should be considered to avoid overestimation of the cancer risks associated with CT scans.

1 July 2015 in Radiology
Verified
Journal Article
Closed access
GDGaël Dournes
Gaël Dournes
DGDavid Grodzki
David Grodzki
JMJulie Macey
Julie Macey
PGPierre-Olivier Girodet
Pierre-Olivier Girodet
MFMichaël Fayon
Michaël Fayon
FLFrançois Laurent
François Laurent
To assess lung magnetic resonance (MR) imaging with a respiratory-gated pointwise encoding time reduction with radial acquisition (PETRA) sequence at 1.5 T and compare it with imaging with a standard volumetric interpolated breath-hold examination (VIBE) sequence, with extra focus on the visibility of bronchi and the signal intensity of lung parenchyma. The study was approved by the local ethics committee, and all subjects gave written informed consent. Twelve healthy volunteers were imaged with PETRA and VIBE sequences. Image quality was evaluated by using visual scoring, numbering of visible bronchi, and quantitative measurement of the apparent contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR). For preliminary clinical assessment, three young patients with cystic fibrosis underwent both MR imaging and computed tomography (CT). Comparisons were made by using the Wilcoxon signed-rank test for means and the McNemar test for ratios. Agreement between CT and MR imaging disease scores was assessed by using the κ test. PETRA imaging was performed with a voxel size of 0.86 mm(3). Overall image quality was good, with little motion artifact. Bronchi were visible consistently up to the fourth generation and in some cases up to the sixth generation. Mean CNR and SNR with PETRA were 32.4% ± 7.6 (standard deviation) and 322.2% ± 37.9, respectively, higher than those with VIBE (P < .001). Good agreement was found between CT and PETRA cystic fibrosis scores (κ = 1.0). PETRA enables silent, free-breathing, isotropic, and submillimeter imaging of the bronchi and lung parenchyma with high CNR and SNR and may be an alternative to CT for patients with cystic fibrosis.

2 February 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
GDGaël Dournes
Gaël Dournes
FMFanny Menut
Fanny Menut
JMJulie Macey
Julie Macey
MFMichaël Fayon
Michaël Fayon
JCJean-François Chateil
Jean-François Chateil
FLFrançois Laurent
François Laurent

1 December 2000 in Brain and Development
Verified
Journal Article
Closed access
DDDelphine Denis
Delphine Denis
JCJean-François Chateil
Jean-François Chateil
MBMuriel Brun
Muriel Brun
OBOlivier Brissaud
Olivier Brissaud
DLDidier Lacombe
Didier Lacombe
JPJean-Michel Pedespan
Jean-Michel Pedespan

24 March 2020 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
PDF file
HRHélène Roumes
Hélène Roumes
UDUrsule Dumont
Ursule Dumont
SSStéphane Sanchez
Stéphane Sanchez
LMLeslie Mazuel
Leslie Mazuel
JBJordy Blanc
Jordy Blanc
ABAnne Karine Bouzier-Sore
Anne Karine Bouzier-Sore
Hypoxic-ischemic (HI) encephalopathy remains a major cause of perinatal mortality and chronic disability in newborns worldwide (1–6 for 1000 births). The only current clinical treatment is hypothermia, which is efficient for less than 60% of babies. Mainly considered as a waste product in the past, lactate, in addition to glucose, is increasingly admitted as a supplementary fuel for neurons and, more recently, as a signaling molecule in the brain. Our aim was to investigate the neuroprotective effect of lactate in a neonatal (seven day old) rat model of hypoxia-ischemia. Pups received intra-peritoneal injection(s) of lactate (40 μmol). Size and apparent diffusion coefficients of brain lesions were assessed by magnetic resonance diffusion-weighted imaging. Oxiblot analyses and long-term behavioral studies were also conducted. A single lactate injection induced a 30% reduction in brain lesion volume, indicating a rapid and efficient neuroprotective effect. When oxamate, a lactate dehydrogenase inhibitor, was co-injected with lactate, the neuroprotection was completely abolished, highlighting the role of lactate metabolism in this protection. After three lactate injections (one per day), pups presented the smallest brain lesion volume and a complete recovery of neurological reflexes, sensorimotor capacities and long-term memory, demonstrating that lactate administration is a promising therapy for neonatal HI insult.

1 March 2015 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ADAnne-Sophie Dutkiewicz
Anne-Sophie Dutkiewicz
KEKhaled Ezzedine
Khaled Ezzedine
JMJuliette Mazereeuw-Hautier
Juliette Mazereeuw-Hautier
JLJean-Philippe Lacour
Jean-Philippe Lacour
SBSebastien Barbarot
Sebastien Barbarot
GPGroupe De Recherche Clinique En Dermatologie Pédiatrique
Groupe De Recherche Clinique En Dermatologie Pédiatrique